

Mitch A Phelps

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3168985/publications.pdf>

Version: 2024-02-01

159
papers

5,634
citations

94433

37
h-index

91884

69
g-index

161
all docs

161
docs citations

161
times ranked

8953
citing authors

#	ARTICLE	IF	CITATIONS
1	PP2A is a therapeutically targetable driver of cell fate decisions via a c-Myc/p21 axis in human and murine acute myeloid leukemia. <i>Blood</i> , 2022, 139, 1340-1358.	1.4	14
2	Serum Albumin: Early Prognostic Marker of Benefit for Immune Checkpoint Inhibitor Monotherapy But Not Chemoimmunotherapy. <i>Clinical Lung Cancer</i> , 2022, 23, 345-355.	2.6	13
3	Discovery of Anticancer Agents of Diverse Natural Origin. <i>Journal of Natural Products</i> , 2022, 85, 702-719.	3.0	19
4	DNA Origami Nanostructures Elicit Dose-Dependent Immunogenicity and Are Nontoxic up to High Doses In Vivo. <i>Small</i> , 2022, 18, .	10.0	40
5	ROR1 targeted immunoliposomal delivery of OSU-2S shows selective cytotoxicity in t(1;19)(q23;p13) translocated B-cell acute lymphoblastic leukemia. <i>Leukemia Research</i> , 2022, 118, 106872.	0.8	2
6	The Neonatal Fc Receptor Is Elevated in Monocyte-Derived Immune Cells in Pancreatic Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7066.	4.1	2
7	Risk factors and predictors of immune-related adverse events: implications for patients with non-small cell lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 861-874.	2.4	6
8	A phase 1 trial of the histone deacetylase inhibitor AR-42 in patients with neurofibromatosis type 2-associated tumors and advanced solid malignancies. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 87, 599-611.	2.3	16
9	Murine cancer cachexia models replicate elevated catabolic pembrolizumab clearance in humans. <i>JCSM Rapid Communications</i> , 2021, 4, 232-244.	1.6	6
10	Inhibition of androgen/AR signaling inhibits diethylnitrosamine (DEN) induced tumour initiation and remodels liver immune cell networks. <i>Scientific Reports</i> , 2021, 11, 3646.	3.3	10
11	Approaches to handling missing or "problematic" pharmacology data: Pharmacokinetics. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2021, 10, 291-308.	2.5	18
12	Phase 2 study of ibrutinib in classic and variant hairy cell leukemia. <i>Blood</i> , 2021, 137, 3473-3483.	1.4	40
13	Phase I evaluation of lenvatinib and weekly paclitaxel in patients with recurrent endometrial, ovarian, fallopian tube, or primary peritoneal Cancer. <i>Gynecologic Oncology</i> , 2021, 162, 619-625.	1.4	7
14	Population Pharmacokinetic Analysis from First-in-Human Data for HDAC Inhibitor, REC-2282 (AR-42), in Patients with Solid Tumors and Hematologic Malignancies: A Case Study for Evaluating Flat vs. Body Size Normalized Dosing. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2021, 46, 807-816.	1.6	1
15	Preclinical activity and a pilot phase I study of pacritinib, an oral JAK2/FLT3 inhibitor, and chemotherapy in FLT3-ITD-positive AML. <i>Investigational New Drugs</i> , 2020, 38, 340-349.	2.6	28
16	Pharmacokinetics and Tolerability of the Novel Non-immunosuppressive Fingolimod Derivative, OSU-2S, in Dogs and Comparisons with Data in Mice and Rats. <i>AAPS Journal</i> , 2020, 22, 92.	4.4	3
17	A phase I study of lenalidomide plus chemotherapy with idarubicin and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome. <i>American Journal of Hematology</i> , 2020, 95, 1457-1465.	4.1	2
18	Early Intervention with Lenalidomide in Patients with High-risk Chronic Lymphocytic Leukemia. <i>Clinical Cancer Research</i> , 2020, 26, 6187-6195.	7.0	3

#	ARTICLE	IF	CITATIONS
19	Association of ANRIL Polymorphism With Overall Survival in Adult Patients With Hematologic Malignancies After Allogeneic Hematopoietic Stem Cell Transplantation. <i>Anticancer Research</i> , 2020, 40, 5707-5713.	1.1	4
20	The Role of Malnutrition and Muscle Wasting in Advanced Lung Cancer. <i>Current Oncology Reports</i> , 2020, 22, 54.	4.0	20
21	Phase I study of AR-42 and decitabine in acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2020, 61, 1484-1492.	1.3	13
22	A phase I study of an oral selective gamma secretase (GS) inhibitor RO4929097 in combination with neoadjuvant paclitaxel and carboplatin in triple negative breast cancer. <i>Investigational New Drugs</i> , 2020, 38, 1400-1410.	2.6	25
23	Pharmacological Prevention of Neonatal Opioid Withdrawal in a Pregnant Guinea Pig Model. <i>Frontiers in Pharmacology</i> , 2020, 11, 613328.	3.5	3
24	Replication Study: Coding-independent regulation of the tumor suppressor PTEN by competing endogenous mRNAs. <i>ELife</i> , 2020, 9, .	6.0	5
25	Comparison of Individualized Versus MAP-Bayesian Predicted AUC of Busulfan in FluBu4 Treated Patients Undergoing Allogeneic Transplant. <i>Blood</i> , 2020, 136, 19-20.	1.4	0
26	Optimising time samples for determining area under the curve of pharmacokinetic data using non-compartmental analysis. <i>Journal of Pharmacy and Pharmacology</i> , 2019, 71, 1635-1644.	2.4	7
27	XRCC1-mediated DNA repair is associated with progression-free survival of multiple myeloma patients after autologous stem cell transplant. <i>Molecular Carcinogenesis</i> , 2019, 58, 2327-2339.	2.7	7
28	Development of a physiologically based pharmacokinetic model for intravenous lenalidomide in mice. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 84, 1073-1087.	2.3	8
29	Population pharmacokinetics of lenalidomide in patients with B-cell malignancies. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 924-934.	2.4	8
30	ROR1-targeted delivery of miR-29b induces cell cycle arrest and therapeutic benefit in vivo in a CLL mouse model. <i>Blood</i> , 2019, 134, 432-444.	1.4	32
31	Letter to the Editor: Exposure-response or clearance-response relationship in immune checkpoint therapy? A comment on "correlation between nivolumab exposure and treatment outcomes in non-small-cell lung cancer"™ by Basak et Al. <i>European Journal of Cancer</i> , 2019, 114, 25-26.	2.8	6
32	The Extracellular RNA Communication Consortium: Establishing Foundational Knowledge and Technologies for Extracellular RNA Research. <i>Cell</i> , 2019, 177, 231-242.	28.9	152
33	A Single Nucleotide Polymorphism in <i>SLC7A5</i> Was Associated With Clinical Response in Multiple Myeloma Patients. <i>Anticancer Research</i> , 2019, 39, 67-72.	1.1	10
34	SUV39H1 Represses the Expression of Cytotoxic T-Lymphocyte Effector Genes to Promote Colon Tumor Immune Evasion. <i>Cancer Immunology Research</i> , 2019, 7, 414-427.	3.4	40
35	ROR1 Targeted Immunoliposomal Delivery of OSU-2S Show Selective Cytotoxicity in t(1;19) Translocated B-ALL. <i>Blood</i> , 2019, 134, 3798-3798.	1.4	0
36	PRMT5 as a druggable target for glioblastoma therapy. <i>Neuro-Oncology</i> , 2018, 20, 753-763.	1.2	75

#	ARTICLE	IF	CITATIONS
37	Phase I Trial of Dabrafenib and Pazopanib in BRAF Mutated Advanced Malignancies. <i>JCO Precision Oncology</i> , 2018, 2, 1-19.	3.0	2
38	Pharmacokineticâ€¦Pharmacodynamic Model of Neutropenia in Patients With Myeloma Receiving Highâ€¦Dose Melphalan for Autologous Stem Cell Transplant. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2018, 7, 748-758.	2.5	11
39	Phyllanthusmin Derivatives Induce Apoptosis and Reduce Tumor Burden in High-Grade Serous Ovarian Cancer by Late-Stage Autophagy Inhibition. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 2123-2135.	4.1	24
40	Cachectic Cancer Patients: Immune to Checkpoint Inhibitor Therapy?. <i>Clinical Cancer Research</i> , 2018, 24, 5787-5789.	7.0	24
41	CD44 positive and sorafenib insensitive hepatocellular carcinomas respond to the ATP-competitive mTOR inhibitor INK128. <i>Oncotarget</i> , 2018, 9, 26032-26045.	1.8	26
42	Polymorphism in <i>ANRIL</i> is associated with relapse in patients with multiple myeloma after autologous stem cell transplant. <i>Molecular Carcinogenesis</i> , 2017, 56, 1722-1732.	2.7	28
43	Plasma pharmacokinetics and bioavailability of verticillin A following different routes of administration in mice using liquid chromatography tandem mass spectrometry. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2017, 139, 187-192.	2.8	3
44	A phase 1 trial of the HDAC inhibitor AR-42 in patients with multiple myeloma and T- and B-cell lymphomas. <i>Leukemia and Lymphoma</i> , 2017, 58, 2310-2318.	1.3	43
45	G-CSF improves safety when you start the day after autologous transplant in multiple myeloma. <i>Leukemia and Lymphoma</i> , 2017, 58, 2947-2951.	1.3	4
46	Achieving the Promise of Therapeutic Extracellular Vesicles: The Devil is in Details of Therapeutic Loading. <i>Pharmaceutical Research</i> , 2017, 34, 1053-1066.	3.5	94
47	Low active loading of cargo into engineered extracellular vesicles results in inefficient miRNA mimic delivery. <i>Journal of Extracellular Vesicles</i> , 2017, 6, 1333882.	12.2	65
48	Rituximab immunotherapy: itâ€™s getting personal. <i>Blood</i> , 2017, 129, 2595-2596.	1.4	1
49	Nitric oxide mediated inhibition of antigen presentation from DCs to CD4+ T cells in cancer and measurement of STAT1 nitration. <i>Scientific Reports</i> , 2017, 7, 15424.	3.3	68
50	Comprehensive toxicity and immunogenicity studies reveal minimal effects in mice following sustained dosing of extracellular vesicles derived from HEK293T cells. <i>Journal of Extracellular Vesicles</i> , 2017, 6, 1324730.	12.2	357
51	Target specificity, in vivo pharmacokinetics, and efficacy of the putative STAT3 inhibitor LY5 in osteosarcoma, Ewing's sarcoma, and rhabdomyosarcoma. <i>PLoS ONE</i> , 2017, 12, e0181885.	2.5	16
52	Oral tetrahydrouridine and decitabine for non-cytotoxic epigenetic gene regulation in sickle cell disease: A randomized phase 1 study. <i>PLoS Medicine</i> , 2017, 14, e1002382.	8.4	107
53	A Phase I/II Trial of Panobinostat in Combination With Lenalidomide in Patients With Relapsed or Refractory Hodgkin Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 347-353.	0.4	23
54	<i>In vitro</i> immunotoxicity assessment of culture-derived extracellular vesicles in human monocytes. <i>Journal of Immunotoxicology</i> , 2016, 13, 652-665.	1.7	13

#	ARTICLE	IF	CITATIONS
55	Discovery and Mechanism of Highly Efficient Cyclic Cell-Penetrating Peptides. <i>Biochemistry</i> , 2016, 55, 2601-2612.	2.5	232
56	A phase I trial of the intravenous Hsp90 inhibitor alvespimycin (17-DMAG) in patients with relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma. <i>Leukemia and Lymphoma</i> , 2016, 57, 2212-2215.	1.3	13
57	Pharmacokinetics of intra-articular betamethasone sodium phosphate and betamethasone acetate and endogenous hydrocortisone suppression in exercising horses. <i>Journal of Veterinary Pharmacology and Therapeutics</i> , 2016, 39, 22-26.	1.3	10
58	Preclinical Pharmacokinetics Study of R- and S-Enantiomers of the Histone Deacetylase Inhibitor, AR-42 (NSC 731438), in Rodents. <i>AAPS Journal</i> , 2016, 18, 737-745.	4.4	11
59	Preparation and Evaluation of a Novel Class of Amphiphilic Amines as Antitumor Agents and Nanocarriers for Bioactive Molecules. <i>Pharmaceutical Research</i> , 2016, 33, 2722-2735.	3.5	3
60	Preferential Delivery of an Opioid Antagonist to the Fetal Brain in Pregnant Mice. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2016, 358, 22-30.	2.5	10
61	Proteomic characterization of circulating extracellular vesicles identifies novel serum myeloma associated markers. <i>Journal of Proteomics</i> , 2016, 136, 89-98.	2.4	68
62	NK Cell-Mediated Antitumor Effects of a Folate-Conjugated Immunoglobulin Are Enhanced by Cytokines. <i>Cancer Immunology Research</i> , 2016, 4, 323-336.	3.4	5
63	Phase 1 Evaluation of Oral Tetrahydropyridine-Decitabine As Non-Cytotoxic Epigenetic Disease Modification for Sickle Cell Disease. <i>Blood</i> , 2016, 128, 124-124.	1.4	2
64	A phase 1 study of AR-42 in patients with advanced solid tumors, including nervous system tumors.. <i>Journal of Clinical Oncology</i> , 2016, 34, 2558-2558.	1.6	4
65	Discovery of Anticancer Agents of Diverse Natural Origin. <i>Anticancer Research</i> , 2016, 36, 5623-5638.	1.1	94
66	Registered report: Coding-independent regulation of the tumor suppressor PTEN by competing endogenous mRNAs. <i>ELife</i> , 2016, 5, .	6.0	43
67	Abstract 2068: Engineering of hairpin loop enhances the loading of endogenously expressed pre-miRNA into extracellular vesicles. , 2016, , .		1
68	CD33 Targeted Immunoliposomal Delivery of OSU-2S, a Non-Immunosuppressive FTY720 Derivative, Mediates Selective Cytotoxicity in Acute Myeloid Leukemia. <i>Blood</i> , 2016, 128, 2748-2748.	1.4	0
69	OSU-T315: a novel targeted therapeutic that antagonizes AKT membrane localization and activation of chronic lymphocytic leukemia cells. <i>Blood</i> , 2015, 125, 284-295.	1.4	19
70	Decitabine priming enhances the antileukemic effects of exportin 1 (XPO1) selective inhibitor selinexor in acute myeloid leukemia. <i>Blood</i> , 2015, 125, 2689-2692.	1.4	47
71	Results of an abbreviated phase-II study with the Akt Inhibitor MK-2206 in Patients with Advanced Biliary Cancer. <i>Scientific Reports</i> , 2015, 5, 12122.	3.3	58
72	The combination of milatuzumab, a humanized anti-CD74 antibody, and veltuzumab, a humanized anti-CD20 antibody, demonstrates activity in patients with relapsed and refractory B-cell non-Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2015, 169, 701-710.	2.5	31

#	ARTICLE	IF	CITATIONS
73	ROR1-targeted delivery of OSU-2S, a nonimmunosuppressive FTY720 derivative, exerts potent cytotoxicity in mantle-cell lymphoma in vitro and in vivo. <i>Experimental Hematology</i> , 2015, 43, 770-774.e2.	0.4	16
74	Reduced occurrence of tumor flare with flavopiridol followed by combined flavopiridol and lenalidomide in patients with relapsed chronic lymphocytic leukemia (CLL). <i>American Journal of Hematology</i> , 2015, 90, 327-333.	4.1	15
75	Phase I dose escalation trial of the novel proteasome inhibitor carfilzomib in patients with relapsed chronic lymphocytic leukemia and small lymphocytic lymphoma. <i>Leukemia and Lymphoma</i> , 2015, 56, 2834-2840.	1.3	13
76	Liquid chromatography-tandem mass spectrometry assay for the simultaneous quantification of simvastatin, lovastatin, atorvastatin, and their major metabolites in human plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2015, 983-984, 18-25.	2.3	24
77	Tumor antigen ROR1 targeted drug delivery mediated selective leukemic but not normal B-cell cytotoxicity in chronic lymphocytic leukemia. <i>Leukemia</i> , 2015, 29, 346-355.	7.2	36
78	Abstract 4406: ROR1 targeted delivery of OSU-2S, a non-immunosuppressive FTY720 derivative, exerts potent cytotoxicity in mantle cell lymphoma in vitro and in vivo. , 2015, , .		0
79	Establishing a clinical pharmacology fellowship program for physicians, pharmacists, and pharmacologists: a newly accredited interdisciplinary training program at the Ohio State University. <i>Advances in Medical Education and Practice</i> , 2014, 5, 191.	1.5	2
80	Irinotecan Pharmacogenetics: A Finished Puzzle?. <i>Journal of Clinical Oncology</i> , 2014, 32, 2287-2289.	1.6	14
81	Flavopiridol can be safely administered using a pharmacologically derived schedule and demonstrates activity in relapsed and refractory non-Hodgkin's lymphoma. <i>American Journal of Hematology</i> , 2014, 89, 19-24.	4.1	26
82	A novel liposomal formulation of FTY720 (Fingolimod) for promising enhanced targeted delivery. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2014, 10, 393-400.	3.3	34
83	A phase I trial of flavopiridol in relapsed multiple myeloma. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 73, 249-257.	2.3	30
84	Sensitive liquid chromatography/mass spectrometry methods for quantification of pomalidomide in mouse plasma and brain tissue. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2014, 88, 262-268.	2.8	21
85	Erlotinib in African Americans With Advanced Non-Small Cell Lung Cancer: A Prospective Randomized Study With Genetic and Pharmacokinetic Analyses. <i>Clinical Pharmacology and Therapeutics</i> , 2014, 96, 182-191.	4.7	21
86	Quantification of OSU-2S, a novel derivative of FTY720, in mouse plasma by liquid chromatography-tandem mass spectrometry. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2014, 98, 160-165.	2.8	4
87	A dose escalation feasibility study of lenalidomide for treatment of symptomatic, relapsed chronic lymphocytic leukemia. <i>Leukemia Research</i> , 2014, 38, 1025-1029.	0.8	11
88	Race and Ethnicity in Cancer Therapy: What Have We Learned?. <i>Clinical Pharmacology and Therapeutics</i> , 2014, 95, 403-412.	4.7	25
89	2-Hour Cryotherapy Effectively Reduces Severe Mucositis Associated with High-Dose Melphalan Followed By Stem Cell Rescue: Results from a Randomized Trial. <i>Blood</i> , 2014, 124, 3960-3960.	1.4	3
90	A phase I trial of dabrafenib (BRAF inhibitor) and pazopanib in BRAF-mutated advanced malignancies.. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS2628-TPS2628.	1.6	0

#	ARTICLE	IF	CITATIONS
91	Standard Pentostatin Dose Reductions in Renal Insufficiency Are Not Adequate: Selected Patients with Steroid-Refractory Acute Graft-Versus-Host Disease. <i>Clinical Pharmacokinetics</i> , 2013, 52, 705-712.	3.5	4
92	Site Specific Discrete PEGylation of ¹²⁴ I-Labeled mCC49 Fab ² Fragments Improves Tumor MicroPET/CT Imaging in Mice. <i>Bioconjugate Chemistry</i> , 2013, 24, 1945-1954.	3.6	16
93	A phase I study of prolonged infusion of triapine in combination with fixed dose rate gemcitabine in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2013, 31, 685-695.	2.6	26
94	Pharmacokinetics and dose escalation of the heat shock protein inhibitor 17-allylamino-17-demethoxygeldanamycin in combination with bortezomib in relapsed or refractory acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2013, 54, 1996-2002.	1.3	41
95	Cyclophosphamide, alvocidib (flavopiridol), and rituximab, a novel feasible chemoimmunotherapy regimen for patients with high-risk chronic lymphocytic leukemia. <i>Leukemia Research</i> , 2013, 37, 1195-1199.	0.8	26
96	A Prospective, Double-Blinded, Observational Clinical Cohort Study of the Association Between Tacrolimus Exposure and CYP3A4, CYP3A5 Genotypes in Adult Hematopoietic Stem Cell Transplant Recipients. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, S380.	2.0	1
97	Comparative cellular pharmacokinetics and pharmacodynamics of siRNA delivery by SPANosomes and by cationic liposomes. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2013, 9, 504-513.	3.3	25
98	A Pharmacokinetic/Pharmacodynamic Model of Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia Patients Treated with Flavopiridol. <i>Clinical Cancer Research</i> , 2013, 19, 1269-1280.	7.0	19
99	Milatuzumab-Conjugated Liposomes as Targeted Dexamethasone Carriers for Therapeutic Delivery in CD74+ B-cell Malignancies. <i>Clinical Cancer Research</i> , 2013, 19, 347-356.	7.0	34
100	Toxicology and Biodistribution Studies for MGH2.1, an Oncolytic Virus that Expresses Two Prodrug-activating Genes, in Combination with Prodrugs. <i>Molecular Therapy - Nucleic Acids</i> , 2013, 2, e113.	5.1	10
101	Tumor Antigen ROR1 Targeted Delivery Of FTY720 Derivative OSU-2S Prolongs Survival In ROR1 Engineered Mouse Model Of Chronic Lymphocytic Leukemia. <i>Blood</i> , 2013, 122, 4168-4168.	1.4	1
102	Abstract 4481: Myeloperoxidase as a determinant for activity of etoposide (VP-16) and other phenolic and non-phenolic anticancer agents: implications for drug-induced leukemogenesis., 2013, .		0
103	Results of a phase I trial of the proteasome inhibitor carfilzomib in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia (SLL).. <i>Journal of Clinical Oncology</i> , 2013, 31, 7077-7077.	1.6	0
104	A Novel Therapeutic Approach In Acute Myeloid Leukemia (AML): In Vivo Preclinical Pharmacokinetic (PK), Pharmacodynamic (PD) and Antileukemia Activities Of Synthetic 2 ^{â€} -O-Methylphosphorothioate Mir-29b. <i>Blood</i> , 2013, 122, 3933-3933.	1.4	0
105	OSU-T315, An Integrin-Linked Kinase (ILK) Inhibitor, Induces Apoptosis By Targeting B Cell Receptor and CD49d Mediated AKT/ERK Activation In Chronic Lymphocytic Leukemia Cells. <i>Blood</i> , 2013, 122, 2523-2523.	1.4	0
106	Acetaminophen Pediatric Dose Selection. <i>Clinical Pediatrics</i> , 2012, 51, 1030-1031.	0.8	2
107	Reovirus-associated reduction of microRNA-let-7d is related to the increased apoptotic death of cancer cells in clinical samples. <i>Modern Pathology</i> , 2012, 25, 1333-1344.	5.5	48
108	Analysis of the transport of and cytotoxic effects for nalbuphine solution in corneal cells. <i>American Journal of Veterinary Research</i> , 2012, 73, 1987-1995.	0.6	2

#	ARTICLE	IF	CITATIONS
109	Institutional Profile: Program in Pharmacogenomics at the Ohio State University Medical Center. <i>Pharmacogenomics</i> , 2012, 13, 751-756.	1.3	5
110	Influence of exercise on the distribution of technetium Tc 99m medronate following intra-articular injection in horses. <i>American Journal of Veterinary Research</i> , 2012, 73, 418-425.	0.6	8
111	Reply to N. Chen et al. <i>Journal of Clinical Oncology</i> , 2012, 30, 341-342.	1.6	1
112	Flavopiridol treatment of patients aged 70 or older with refractory or relapsed chronic lymphocytic leukemia is a feasible and active therapeutic approach. <i>Haematologica</i> , 2012, 97, 423-427.	3.5	17
113	Pharmacokinetics of methylprednisolone acetate after intra-articular administration and subsequent suppression of endogenous hydrocortisone secretion in exercising horses. <i>American Journal of Veterinary Research</i> , 2012, 73, 1453-1461.	0.6	12
114	Pharmacokinetics and Tissue Disposition of Lenalidomide in Mice. <i>AAPS Journal</i> , 2012, 14, 872-882.	4.4	29
115	Development and validation of sensitive liquid chromatography/tandem mass spectrometry method for quantification of bendamustine in mouse brain tissue. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2012, 905, 141-144.	2.3	12
116	A dose-finding, pharmacokinetic and pharmacodynamic study of a novel schedule of flavopiridol in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2012, 30, 629-638.	2.6	24
117	Structurally Modified Curcumin Analogs Inhibit STAT3 Phosphorylation and Promote Apoptosis of Human Renal Cell Carcinoma and Melanoma Cell Lines. <i>PLoS ONE</i> , 2012, 7, e40724.	2.5	80
118	Priming of Mir-181a in Acute Myeloid Leukemia (AML) to Increase Chemosensitivity: A Phase I Trial of Lenalidomide (LEN) Followed by Idarubicin and Cytarabine.. <i>Blood</i> , 2012, 120, 2619-2619.	1.4	0
119	Pharmacogenomic testing: Relevance in medical practice. <i>Cleveland Clinic Journal of Medicine</i> , 2011, 78, 243-257.	1.3	126
120	Pharmacokinetics of oral ivabradine in healthy cats. <i>Journal of Veterinary Pharmacology and Therapeutics</i> , 2011, 34, 469-475.	1.3	9
121	6Î²-Naltrexol, a Peripherally Selective Opioid Antagonist that Inhibits Morphine-Induced Slowing of Gastrointestinal Transit: An Exploratory Study. <i>Pain Medicine</i> , 2011, 12, 1727-1737.	1.9	24
122	Risk factors for tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with the cyclin-dependent kinase inhibitor, flavopiridol. <i>Leukemia</i> , 2011, 25, 1444-1451.	7.2	42
123	Characterization of Silvestrol Pharmacokinetics in Mice Using Liquid Chromatography-Tandem Mass Spectrometry. <i>AAPS Journal</i> , 2011, 13, 347-56.	4.4	41
124	Resistance to the Translation Initiation Inhibitor Silvestrol is Mediated by ABCB1/P-Glycoprotein Overexpression in Acute Lymphoblastic Leukemia Cells. <i>AAPS Journal</i> , 2011, 13, 357-64.	4.4	63
125	miR-221 Silencing Blocks Hepatocellular Carcinoma and Promotes Survival. <i>Cancer Research</i> , 2011, 71, 7608-7616.	0.9	206
126	Multi-Institutional Phase II Study of Selumetinib in Patients With Metastatic Biliary Cancers. <i>Journal of Clinical Oncology</i> , 2011, 29, 2357-2363.	1.6	272

#	ARTICLE	IF	CITATIONS
127	Phase I Trial of Lenalidomide and CCI-779 in Patients With Relapsed Multiple Myeloma: Evidence for Lenalidomide-CCI-779 Interaction via P-Glycoprotein. <i>Journal of Clinical Oncology</i> , 2011, 29, 3427-3434.	1.6	77
128	Abstract 4711: Silencing of miR-221 with anti-microRNA oligonucleotides is an effective therapeutic for hepatocellular carcinoma. , 2011, , .		0
129	Abstract 5473: The contribution of P-glycoprotein to clinical pharmacokinetic interactions between lenalidomide and temsirolimus. , 2011, , .		0
130	Abstract 124: Cellular context in epigenetics: Per-cell quantitation of miR-let-7d and its putative target in caspase-3 in reovirus-infected cancer cells. , 2011, , .		0
131	Abstract 1721: Resistance to silvestrol is mediated by MDR1/Pgp over-expression in a lymphoblastic leukemia cell line and is reversible by treatment with rapamycin. , 2011, , .		0
132	Phase I clinical and pharmacokinetic study of a novel schedule of flavopiridol in relapsed or refractory acute leukemias. <i>Haematologica</i> , 2010, 95, 1098-1105.	3.5	50
133	Flavopiridol Pharmacogenetics: Clinical and Functional Evidence for the Role of SLCO1B1/OATP1B1 in Flavopiridol Disposition. <i>PLoS ONE</i> , 2010, 5, e13792.	2.5	45
134	Dose Escalation of Lenalidomide in Relapsed or Refractory Acute Leukemias. <i>Journal of Clinical Oncology</i> , 2010, 28, 4919-4925.	1.6	82
135	REO-10: A Phase I Study of Intravenous Reovirus and Docetaxel in Patients with Advanced Cancer. <i>Clinical Cancer Research</i> , 2010, 16, 5564-5572.	7.0	120
136	Phase I Trial of Flavopiridol In Relapsed Myeloma: Brief Response In t(4;14) with Significant Neutropenia. <i>Blood</i> , 2010, 116, 1933-1933.	1.4	1
137	A phase I/II dose escalation study of apolizumab (Hu1D10) using a stepped-up dosing schedule in patients with chronic lymphocytic leukemia and acute leukemia. <i>Leukemia and Lymphoma</i> , 2009, 50, 1958-1963.	1.3	32
138	Phase II Study of Flavopiridol in Relapsed Chronic Lymphocytic Leukemia Demonstrating High Response Rates in Genetically High-Risk Disease. <i>Journal of Clinical Oncology</i> , 2009, 27, 6012-6018.	1.6	212
139	A novel liposomal formulation of flavopiridol. <i>International Journal of Pharmaceutics</i> , 2009, 365, 170-174.	5.2	43
140	Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia. <i>Blood</i> , 2009, 113, 2637-2645.	1.4	152
141	Development and validation of a sensitive liquid chromatography/mass spectrometry method for quantitation of flavopiridol in plasma enables accurate estimation of pharmacokinetic parameters with a clinically active dosing schedule. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2008, 868, 110-115.	2.3	16
142	Development and validation of a rapid and sensitive high-performance liquid chromatography-mass spectroscopy assay for determination of 17-(allylamino)-17-demethoxygeldanamycin and 17-(amino)-17-demethoxygeldanamycin in human plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2008, 871, 15-21.	2.3	7
143	Inhibitors of Tubulin Assembly Identified through Screening a Compound Library. <i>Chemical Biology and Drug Design</i> , 2008, 72, 513-524.	3.2	22
144	Intracellular Processing of Riboflavin in Human Breast Cancer Cells. <i>Molecular Pharmaceutics</i> , 2008, 5, 839-848.	4.6	29

#	ARTICLE	IF	CITATIONS
145	Development and Validation of a Highly Sensitive Liquid Chromatography/Mass Spectrometry Method for Simultaneous Quantification of Lenalidomide and Flavopiridol in Human Plasma. <i>Therapeutic Drug Monitoring</i> , 2008, 30, 620-627.	2.0	27
146	Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. <i>Blood</i> , 2007, 109, 399-404.	1.4	367
147	Flavopiridol in Chronic Lymphocytic Leukemia. <i>Clinical Leukemia</i> , 2007, 1, 292-297.	0.2	4
148	Preliminary Results of a Phase II Study of Flavopiridol (Alvocidib) in Relapsed Chronic Lymphocytic Leukemia (CLL): Confirmation of Clinical Activity in High-Risk Patients and Achievement of Complete Responses (CR).. <i>Blood</i> , 2007, 110, 3104-3104.	1.4	3
149	Antikinetoplastid antimetabolic activity and metabolic stability of dinitroaniline sulfonamides and benzamides. <i>Bioorganic and Medicinal Chemistry</i> , 2006, 14, 5699-5710.	3.0	20
150	Recognition, Cointernalization, and Recycling of an Avian Riboflavin Carrier Protein in Human Placental Trophoblasts. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2006, 317, 465-472.	2.5	21
151	Flavopiridol Can Be Safely Dose Escalated in Relapsed CLL Patients: Achievement of Target Cmax Results in Improved Clinical Activity.. <i>Blood</i> , 2006, 108, 2845-2845.	1.4	4
152	Updated Results of a Phase I Study of Flavopiridol in Acute Leukemias Using a Novel, Pharmacokinetically Derived Schedule: Clinical Activity Including Hyperacute Tumor Lysis Syndrome (TLS), Pharmacokinetics (PK), and Pharmacodynamics (PD).. <i>Blood</i> , 2006, 108, 4578-4578.	1.4	0
153	Selective Androgen Receptor Modulator Treatment Improves Muscle Strength and Body Composition and Prevents Bone Loss in Orchidectomized Rats. <i>Endocrinology</i> , 2005, 146, 4887-4897.	2.8	173
154	Topology Scanning and Putative Three-Dimensional Structure of the Extracellular Binding Domains of the Apical Sodium-Dependent Bile Acid Transporter (SLC10A2). <i>Biochemistry</i> , 2004, 43, 11380-11392.	2.5	62
155	A Novel Rhodamine~Riboflavin Conjugate Probe Exhibits Distinct Fluorescence Resonance Energy Transfer that Enables Riboflavin Trafficking and Subcellular Localization Studies. <i>Molecular Pharmaceutics</i> , 2004, 1, 257-266.	4.6	24
156	Favorable Effects of Weak Acids on Negative-Ion Electrospray Ionization Mass Spectrometry. <i>Analytical Chemistry</i> , 2004, 76, 839-847.	6.5	182
157	Cytoskeletal motors and cargo in membrane trafficking: opportunities for high specificity in drug intervention. <i>Drug Discovery Today</i> , 2003, 8, 494-502.	6.4	22
158	Involvement of Endocytic Organelles in the Subcellular Trafficking and Localization of Riboflavin. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2003, 306, 681-687.	2.5	31
159	Modeling of active transport systems. <i>Advanced Drug Delivery Reviews</i> , 2002, 54, 329-354.	13.7	76